Metabolism of collagen is altered in hypertensives with increased intima media thickness

References

• Woodwell D. A. National Ambulatory Medical Care Survey. 1996 Summary. Advance data from Vital and Health Statistics; No 295. National Center for Health Statistics, Hyattsville, Maryland 1997
   Google Scholar
• Gibbons G. H., Dzau V. J. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431–1438
   PubMed Web of Science ®Google Scholar
• Weber K. T., Brilla C. G., Campbell S. E., Zhou G., Matsubara L., Guarda E. Pathologic hypertrophy with fibrosis: The structural basis for myocardial failure. Blood Press 1992; 1: 75–85
   PubMedGoogle Scholar
• Galis Z. S., Sukhova G. K., Lark M. W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493–2503
   PubMed Web of Science ®Google Scholar
• Naghavi M., Libby P., Falk E., Casscells S. W., Litovsky S., Rumberger J., et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664–1672
   PubMed Web of Science ®Google Scholar
• Orbe J., Fernandez L., Rodriguez J. A., Rabago G., Belzunce M., Monasterio A., et al. Different expression of MMPs/TIMP‐1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 2003; 170: 269–276
   PubMed Web of Science ®Google Scholar
• Weber K. T. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264–272
   PubMed Web of Science ®Google Scholar
• Li Y. Y., McTiernan C. F., Feldman A. M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214–224
   PubMed Web of Science ®Google Scholar
• Lopez B., Gonzales A., Querejeta R., Diez J. The use of collagen‐derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23: 1445–1451
   PubMed Web of Science ®Google Scholar
• Querejeta R., Varo N., Lopez B. Serum carboxy‐terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729–1735
   PubMed Web of Science ®Google Scholar
• Schwartzkopff B., Motz W., Frenzel H. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88: 993–1003
   PubMed Web of Science ®Google Scholar
• Pearlman E. S., Weber K. T., Janicki J. S., Pietra G. G., Fishman A. P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 1982; 46: 158–164
   PubMed Web of Science ®Google Scholar
• Weber K. T., Janicki J. S., Pick R., Abrahams C., Shroff S. G., Bashey R. I., et al. Collagen in the hypertrophied pressure‐overloaded myocardium. Circulation 1987; 75: 40–47
   PubMed Web of Science ®Google Scholar
• Caspari P. G., Newcomb M., Gibson K., Harris P. Collagen in the normal and hypertrophied human ventricle. Cardiovasc Res 1977; 11: 554–558
   Google Scholar
• Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566
   PubMed Web of Science ®Google Scholar
• Simon A., Gariepy J., Chironi G., Megnien J. L., Levenson J. Intima‐media thickness: A new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20: 159–169
   PubMed Web of Science ®Google Scholar
• 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–183
   PubMed Web of Science ®Google Scholar
• Sahn D. J., DeMaria A., Kisslo J. Recommendations regarding quantitation in M‐mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083
   PubMed Web of Science ®Google Scholar
• Devereux R. B., Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613–618
   PubMed Web of Science ®Google Scholar
• Devereux R. B., Dahlof B., Levy. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78: 61–65
   PubMed Web of Science ®Google Scholar
• Diez J., Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35: 202–205
   PubMed Web of Science ®Google Scholar
• Parfitt A. M., Simon L. S., Villanueva A. R., Krane S. M. Procollagen type I carboxy‐terminal extension peptide in serum as marker of collagen biosynthesis in bone: Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427–436
   PubMed Web of Science ®Google Scholar
• Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222–1226
   PubMed Web of Science ®Google Scholar
• Tonstad S., Joakimsen O., Stensland‐Bugge E., Ose L., Bonaa K. H., Leren T. P. Carotid intima‐media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest 1998; 28: 971–979
   Google Scholar
• Lindsay M. M., Maxwell P., Dunn F. G. TIMP‐1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136–141
   PubMed Web of Science ®Google Scholar
• Timms P. M., Wright A., Maxwell P., Campbell S., Dawnay A. B., Srikanthan V. Plasma tissue inhibitor of metalloproteinase‐1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002; 15: 269–272
   PubMed Web of Science ®Google Scholar
• Sundstrom J., Evans J. C., Benjamin E. J., Levy D., Larson M. G., Sawyer D. B., et al. Relations of plasma total tissue inhibitor of metalloproteinases‐1 levels to cardiovascular risk factors and echocardiographic measures: The Framingham Heart Study. Eur Heart J 2004; 25: 1509–1516
   PubMed Web of Science ®Google Scholar
• Szmigielski C., Raczkowska M., Styczynski G., Pruszczyk P., Gaciong Z. Correspondence to: Relations of plasma total TIMP‐1 levels to cardiovascular risk factors and echocardiografic measures: The Framingham Heart Study. Eur Heart J 2005; 26: 418
   PubMed Web of Science ®Google Scholar
• Varo N., Iraburu M. J., Varela M., Lopez B., Etayo J. C., Diez J. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35: 1197–1202
   PubMed Web of Science ®Google Scholar
• Murawaki Y., Ikuta Y., Idobe Y., Kitamura Y., Kawasaki H. Tissue inhibitor of metalloproteinase‐1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213–1219
   PubMed Web of Science ®Google Scholar
• Lombardi R., Betocchi S., Losi M. A., Tocchetti C. G., Aversa M., Miranda M., et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003; 108: 1455–1460
   Google Scholar
• Amanuma S., Sekiguchi M., Ogasawara S., Honda M., Hosoda S. Biventricular endomyocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J 1994; 70 Supp 1: S67–S71
   Google Scholar
• Laviades C., Varo N., Diez J. Transforming growth factor beta in hypertensives with cardio‐renal damage. Hypertension 2000; 36: 517–522
   PubMed Web of Science ®Google Scholar
• Lopez B., Querejeta R., Varo N., Gonzalez A., Larman M., Martinez Ubago J. L., et al. Usefulness of serum carboxy‐terminal propeptide of procollagen type I to assess the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286–291
   PubMed Web of Science ®Google Scholar
• Jensen L. T., Horslev‐Petersen K., Toft P., Bentsen K. D., Grande P., Simonsen E. E., et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 1990; 81: 52–57
   Google Scholar
• Olsen M. H., Christensen M. K., Wachtell K., Tuxen C., Fossum E., Bang L. E., et al. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: A LIFE substudy. J Hum Hypertens 2005; 19: 301–307
   PubMed Web of Science ®Google Scholar
• Bishop J. E., Kiernan L. A., Montgomery H. E., Gohlke P., McEwan J. R. Raised blood pressure, not renin‐angiotensin systems, causes cardiac fibrosis in TGRm(Ren2)27 rats. Cardiovasc Res 2000; 47: 57–67
   Google Scholar
• Wei S., Chow L. T., Shum I. O., Qin L., Sanderson J. E. Left and right ventricular collagen type I/III ratios and remodeling post‐myocardial infarction. J Card Fail 1999; 5: 117–126
   Google Scholar
• Weber K. T., Sun Y., Guarda E., Katwa L. C., Ratajska A., Cleutjens J. P., et al. Myocardial fibrosis in hypertensive heart disease: An overview of potential regulatory mechanisms. Eur Heart J 1995; 16(Suppl C)24–28
   Google Scholar